Back to discover
Disease
Adverse effect
Late-stage therapeutic development
Also known as adverse reaction.
11
Clinical trials
12
Associated genes
2
Related proteins
Current focus
Cholinesterase biologyProstacyclin biologyTherapeutic development
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 1 clinical trial expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Major developments
Upcoming trial readoutImportant
Results expected Q1 20272026-01-20
Major clinical milestoneWorth watching
Primary completion2025-12-31
Clinical MilestonesViewHide
Results expected
- 2026-01-20Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)Results expected Q1 2027
Recently completed
Activity timeline2
- 2026-01-20ClinicalPropofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)Results expected Q1 2027
- 2025-12-31ClinicalPre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Crohn's DiseasePrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
11
2
7
6
Late-stage studies
Recruiting
Recently completed
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
adverse reaction
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.